Return on equity (ROE) is the profit a company earns for every dollar of shareholder money invested in it, shown as a percentage. It is net income divided by shareholder equity, and the table shows both amounts: the profit earned and the equity it was earned on. A higher ROE means more profit per dollar of equity, but ROE also rises when equity shrinks through buybacks, dividends or losses, and it has no meaning for a company with negative equity. Quarterly points divide the trailing four quarters of net income by the balance at that quarter end; annual points divide the filed fiscal-year net income by the fiscal-year-end balance.
LENZ Therapeutics, Inc. roe for the quarter ending 2026-06-30 was -57.47%, a change of -32.08% year-over-year.
LENZ Therapeutics, Inc. roe for the quarter ending 2026-03-31 was -44.22%, a change of -19.36% year-over-year.
LENZ Therapeutics, Inc. roe for the quarter ending 2025-12-31 was -28.88%, a change of -4.50% year-over-year.
LENZ Therapeutics, Inc. roe for the quarter ending 2025-09-30 was -30.36%, a change of -2.12% year-over-year.
LENZ Therapeutics, Inc. roe for fiscal 2025 was -28.88%, a change of -4.50% from fiscal 2024.
LENZ Therapeutics, Inc. roe for fiscal 2024 was -24.39%, a 132.31% decline from fiscal 2023.
LENZ Therapeutics, Inc. roe for fiscal 2023 was 75.47%, a 81.95% decline from fiscal 2022.
LENZ Therapeutics, Inc. roe for fiscal 2022 was 418.11%, a change of 436.53% from fiscal 2021.